SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-117723
Filing Date
2024-10-28
Accepted
2024-10-28 16:06:38
Documents
13
Period of Report
2024-10-28
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20241028.htm   iXBRL 8-K 49309
2 EX-3.1 kzr-ex3_1.htm EX-3.1 13038
3 EX-99.1 kzr-ex99_1.htm EX-99.1 10127
  Complete submission text file 0000950170-24-117723.txt   193570

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20241028.xsd EX-101.SCH 24893
15 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20241028_htm.xml XML 4717
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 241400915
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)